Boehringer Ingelheim AB
The primary business is focused on human pharmaceuticals including prescription medicines and products for consumer health care as well as on chemicals and biopharmaceuticals for industrial customers. In addition there is a divers portfolio of animal health products.
The company is established in respiratory and cardiovascular medicine. New products have also been introducted in other indication areas, such as HIV/aids, rheumatic diseases, neurology and particularly stroke - both acute treatment and secondary prevention.